Cobalt-mediated suppression of IFN-γ-JAK-STAT1 signaling reprograms IDO1-driven immunosuppression for metalloimmunotherapy.

Jiang, Tianyi; Huang, Xiaowan; Wu, Zhixin; Abudusaimaiti, Gulinaizaier; Song, Yang; Duan, Hongtao; Zhou, Yuping; Chen, Yaoxu et al. · Sci Adv · 2026

basic_science · Level V

Where this comes from

Abstract

Metal ions are increasingly recognized as regulators of immune function, yet their application in cancer immunotherapy remains underexplored. Here, we identified cobalt ions (Co<sup>2+</sup>) as potent suppressors of IFN-γ-induced IDO1 expression through systematic screening of biologically relevant metal ions. Across multiple cancer cell lines, Co<sup>2+</sup> notably reduced IDO1 expression and kynurenine production. Mechanistically, Co<sup>2+</sup> destabilized IFNGR1 and inhibited IFN-γ-JAK-STAT1 signaling, thereby restoring kynurenine/tryptophan metabolic balance and alleviating immunosuppression of CD8<sup>+</sup> T cell. These effects reprogrammed the immunosuppressive tumor microenvironment toward enhanced cytotoxic T cell activity. To minimize the toxicity associated with free Co<sup>2+</sup>, we developed ConaHA, a hyaluronic acid-based nanoparticle platform enabling sustained and tumor-targeted cobalt delivery. ConaHA enhanced cobalt-mediated immune checkpoint blockade in vivo, resulting in notably improved antitumor efficacy in subcutaneous Panc02, MC38, and B16F10 tumor models and KPC (<i>LSL-Kras</i><sup><i>G12D/+</i></sup>; <i>LSL-Trp53</i><sup><i>R172H/+</i></sup>; <i>Pdx-1-Cre</i>) models. Collectively, these findings reveal a previously unrecognized immunoregulatory role of Co<sup>2+</sup> and establish a promising framework for metalloimmunotherapy through modulation of metal-immune signaling pathways.

Medical subject headings